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A B S T R A C T   
Background: The emergence of SARS-CoV-2 pandemic has upset health systems around the world and caused 
immeasurable losses and costs. Until a vaccine will become available, the recommended prevention measures 
remain physical distancing and enhanced hygiene. 
Methods and findings: The proteic structure external to the virus is the main target that may eventually lead to 
reduce or block its replication in the upper airways. We developed a protocol based of repeated steam inhalation 
cycles aimed at reducing the risk of progression to full blown infection if performed soon after contagion. The 
protocol has been used in a single-center open label trial on ten infected asymptomatic or pauci-symptomatic 
health care professionals. 
Conclusions: The promising results we obtained with this easily accessible, non-invasive and inexpensive pro-
cedure should prompt controlled trials.   
1. Introduction 
The new coronavirus (SARS-CoV-2) causing COVID-19 is an RNA 
virus coated with a capsid and a peri-capsid crossed by glycoprotein 
structures. The external proteic structure, which attacks human cells, is 
a potential target to therapeutic interventions against virus replication 
in airways. 
Since high temperature can cause irreversible denaturation of pro-
teins and loss of SARS CoV and SARS CoV-2 infectivity was obtained 
after heating at 56 ◦C for 15 and 30 min in liquid environments 
respectively [1–3], we designed a simple protocol aimed at damaging 
SARS-CoV-2 capsid through steam inhalation cycles. Although the 
ominous consequences of COVID 19 infections has directed medical 
attention toward solidly established medical approaches, the European 
Pharmacopoeia VI edition also quotes steam inhalations as a procedure 
to treat of respiratory diseases [4]. Based on these suggestions we 
established a single-centered open label interventional study with the 
limited objective of enrolling up to 10 asymptomatic or pauci- 
symptomatic healthcare professionals in whom RN-swab revealed a 
SARS-CoV-2 infection. The study protocol consisted of exposure of 
airway mucosae to humidified steam through steam inhalation for at 
least 20 min (5 cycles of 4 min) within 1 h for at least 4 consecutive days. 
The ensuing reduction of viral shedding was measured by real time PCR 
on rhino-pharyngeal (RN) swab self-sampling [5] 24 h after each cycle of 
treatment. 
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2. Patients and methods 
This single-centered open label interventional study had the limited 
objective of enrolling up to 10 adults in whom RN-swab (eSwab, Copan, 
Italy) revealed a SARS-CoV-2 infection during a systematic screening of 
healthcare professionals (physicians, MD; pediatric nurses, PN) actively 
working at Meyer Children’s University Hospital, Florence, consecu-
tively screened between March–April 2020. 
The protocol was proposed to the first 10 asymptomatic or pauci- 
symptomatic (up to 2–3 mild to moderate symptoms) healthcare pro-
fessionals (7 PN and 3 MD) with a positive RN-swab (inclusion criteria) 
providing them with informed consent, protocol instructions plus a 
video tutorial and a form to record symptoms and protocol adherence. 
We set as exclusion criteria for enrolment a history of pre-existing al-
lergies and/or asthma, ongoing drug therapies against SARS-CoV-2, and 
individuals with multiple symptoms consistent with COVID infection. 
The study protocol consisted of exposure of airway mucosae to hu-
midified steam through inhalation for at least 20 min (4 cycles of 5 min 
or 5 cycles of 4 min) within 1 h, with a temperature maintained between 
55 and 65 ◦C in the first 4/5 min after initiation of water boiling 
(experimental measurements in triplicate). The patient was asked to 
drape the towel over the back of his/her head lowering toward the hot 
steam down to about 25 to 30 cm from the water. 
The primary outcome was a reduction of viral shedding after 4 days 
(at least 6 Cycle Threshold Values measured with RT-PCR) and the 
secondary outcome complete virus elimination after the 4-day protocol. 
Seven out of 10 subjects met the inclusion criteria (nos. 1–7). Subject 
8 (PN) declared to be allergic; subject 9 (MD), after following the pro-
tocol for three days, reported to have also started hydroxychlorochine 
and azytromicine treatment since day 1; subject 10 (PN) manifested 
more than three symptoms, self-reported to be from moderate to severe, 
which likely indicated active exponential viral growth. While not 
satisfying inclusion criteria, these three individuals asked to join the 
protocol all the same, based on its simplicity and potential benefits. 
Their results will be dealt with separately. 
3. Results 
Of 1292 screened healthcare professionals, the first 10 with a SARS- 
CoV-2 positive RN-swab were enrolled in the study. The mean age of the 
7 patients (6 women) completing the protocol, was 44.4 (SD 12.1) years. 
One patient (no. 5) was asymptomatic before and after the protocol, five 
exhibited one or two mild symptoms including dry cough (1/5), sore 
throat (1/5), headache (1/5), anosmia (2/5), ageusia (2/5), tiredness 
(2/5), soreness/muscle pain (1/5), and nasal congestion (1/5). One 
patient (no. 4) reported moderate headache and generalised muscle 
pain. All 6 patients with symptoms reported clinical improvement at the 
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The arrows indicate the days in which the steam inhalation treatment was made;  HC is hydroxychlorochine; A is Azytromicine; + Self swabs pre treatment; Day 0 is the day of the official swab
Fig. 1. 1A: Viral shedding diagram from patients 2, 3, 5, 6 and 7. All five patients performed the protocol (4 cycles/5 min each) on days 1, 2, 3 and 4 measuring the 
effect of treatment on days 2, 3, 4 and 5. A new swab on day 10 confirmed short term negativity. 
1B: Viral shedding diagram from patient 4. The patient, who exhibited a low viral load (35 CT), was asked to perform a self-swabbing procedure before starting the 
protocol to test his/her ability to carry on autonomously the procedure on day 2. A new swab on day 10 confirmed short term negativity. 
1C: Viral shedding diagram from patient 1. The patient with an official moderate viral load (27 CT) was asked to perform self-swabbing before starting the protocol, 
to test his/her ability to carry on autonomously the procedure on days 3 and 4. A new swab on day 11 confirmed short-term negativity. 
1D: Viral shedding diagram from patient 8. This patient did not complete the cycle’s protocol due to allergies and intolerance to a prolonged exposure to humidified 
steam: on day 1 this patient followed 11 min treatment divided in three cycle 5, 3 and 3 min respectively. On day 2 followed 13 min treatment divided in three cycles 
5, 5 and 3 min respectively; on day 3, two cycles 5 and 4 min; on day 4, three cycles, 3 min each. On day 5 had a new low viral load positive swab and on day 10 she 
tested negative. 
1E: Viral shedding diagram from patient 9. Subject performed the protocol for overall 11 days together with drug treatment based on hydroxychlorochine and 
azytromicine. She resulted in all positive swabs. She tested negative after 15 and 17 days. 
1F: Viral shedding diagram in patient 10. This patient, who exhibited a high viral load (21 CT) was asked to perform a self-swabbing procedure (on day 2 and day 3) 
before starting the protocol to test his/her ability to carry on autonomously the procedure on day 3 and 4. This patient performed the protocol for overall 7 days 
testing negative since the 5th day of treatment. 
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declared persisting anosmia and ageusia; one reported mild muscle pain 
and nasal congestion. All seven patients achieved both outcomes, testing 
negative after the first day of steam inhalation (4 consecutive RN- 
swabs). All were asked to evaluate their negativity 3–5 days after pro-
tocol conclusion (Fig. 1A–C). 
Patient 8 (PN, 39 years old, allergic) experienced mild headache and 
nasal congestion, both of which resolved at the end of the study, after 
three steam inhalations on day 1 (5 + 3 + 3 min), three on day 2 (5 + 5 
+ 3 min), two on day 3 (5 + 4 min), three on day 4 (3 + 3+ 3 min). A first 
negative swab after the first session, was followed by a new weak pos-
itivity after 3 days. This patient stopped the protocol on day 5 and un-
derwent an additional swab on day 10, which resulted negative 
(Fig. 1D). 
Patient 9 (MD, 36 years old) reported moderate tiredness, headache 
and mild muscle pain. On the third day of the protocol this patient 
started hydroxychlorochine (HC) and azytromicine (AZ) (for 9 days and 
3 days, respectively), which resulted in her being dropped from our 
study. This lady continued the steam inhalation protocol up to complete 
clearance on day 5, as she felt her symptoms had been eased. From day 6 
she reported nasal congestion, muscle/bone pain, progressive anosmia 
and ageusia, which diminished till day 11. Steam inhalation was stopped 
on day 12. All swabs during the experimental protocol resulted positive 
(Fig. 1E), while further swabs on days 15 and 17 tested negative. 
Patient 10 (PN, 38 years old) tested positive at first swab, 13 days 
after close contact with a known infected, symptomatic individual. 
When asked to participate to the study, this patient reported moderate 
muscle pain, tiredness, nasal congestion, sinusitis, anosmia, hypogeusia, 
and sore throat, with 4 days of fever (>38 ◦C) immediately prior to the 
official swab. All the swabs during the study protocol were positive 
(Fig. 1F). This lady continued the steam inhalation protocol, which she 
motivated with a beneficial effect on symptoms (complete clearance on 
day 10). Three additional swabs on days 8, 9 and 10 were negative 
(Fig. 1F). 
4. Discussion 
Lowff’s model, demonstrates that raising the mucosal temperature to 
43 ◦C for three periods of 30 min each, at two-hour intervals, blocks the 
replication of rhinoviruses after virus inoculation [6,7]. Since SARS- 
COV-2 proved to be thermolabile in liquid environment [3], we hy-
pothesized our procedure, if performed soon after contagion, would 
reduce the risk of progression to full blown infection. However, conta-
gion occurs most often unknowingly, which does not allow a timely 
preventive procedure, unless carried on systematically in at risk in-
dividuals (for example healthcare professionals working in COVID units 
or personnel in contact with the public). Although applying the Lowff’s 
model to benefit pre-symptomatic and untested individuals would be 
unrealistic in a pandemic context, we hypothesized it would still be 
effective in abating viral load in asymptomatic or pauci-symptomatic 
individuals who test positive to RN-swab and are both potentially in-
fectious and at risk of symptoms worsening. 
However, controlled trials of repeated steam inhalations at 43 ◦C for 
the treatment of airway viruses have generated controversial results 
[8,9]. On the other hand, the popular “grandma” remedy is variably 
applied and often implies a “one shot” steam inhalation procedure, 
exposing the upper airways mucosae for a short time at uncontrolled 
temperature. Neither approach may be effective, however, since 
repeated cycles at higher temperature have higher chances of weakening 
or halting virus spread. Our small study suggests that a protocol based on 
cycles of steam inhalation at temperature 55–65 ◦C might indeed be 
beneficial in halting SARS-CoV-2 virus infection in the upper airway 
mucosae during the initial stages of infection and possibly preventing 
further spread. It could also be helpful in pauci-symptomatic subjects 
during the last period of infection, when the immune system is already 
active against the virus but its presence is still detectable in the upper 
respiratory tract. Since steam cannot reach the bronchial tree, bronchi 
and lungs, it is unlikely it could be beneficial once the infection has 
reached the deep internal airway mucosa. 
Our observation is only preliminary, it has obvious limitations and 
the beneficial effects we observed need confirmation in a controlled 
trial. In addition, self-swabbing procedures, although officially allowed 
in the interim guidelines for collecting, handling and testing clinical 
specimens from persons affected by COVID-19 [5], are a potential source 
of bias, which we tried to limit, by randomly asking 3/10 subjects (nos. 
1, 4 and 10) to self-swab before starting the protocol procedures. A 
spontaneous remission from the virus 24 h after the treatment began is 
possible, but unlikely for all 7 enrolled patients. 
Finally, the protocol cannot be intended to lead to an eradication of 
the virus from the body, as the steam inhalation procedure can only 
reach upper airways. However, the proposed steam inhalation cycles are 
safe (provided care is used against the possible burns, especially in 
children), inexpensive and easily self-managed. This simple approach, 
only tested in a small sample and in a biased population, might help 
easing the consequences of SARS-CoV-2 infection, if applied early in at 
risk individuals in whatever healthcare setting, especially in low income 
countries with limited access to equipped hospitals or intensive care 
units. Unequivocal proof of efficacy would require a controlled trial on a 
larger scale. 
Should our preliminary observations be confirmed the protocol 
could be used against COVID19 or other viral infections using vapo-
therm masks, where temperature, time of exposure and size of steam 
particles can be set and monitored. 
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